Abstract This study aimed to establish an efficient in vitro cell-based assay to measure the activity of teriparatide (PTH1–34). In this study, a rat osteosarcoma cell line (UMR-106) was treated with various concentrations of PTH1–34, and the biological activity of PTH1–34 was determined by quantitatively measuring intracellular cyclic adenosine monophosphate levels using a time-resolved fluoroimmunoassay. A four-parameter fitting analysis was used to calculate the relative potency of the samples. The experimental conditions were optimized. The method's specificity, relative accuracy, precision, and linearity were validated. Our data suggested that this method had good specificity, a relative bias of relative accuracy ranging from −0.8 to 1.4%, a correlation coefficient for the linear regression equation of 0.9953, a geometric coefficient of variation for intermediate precision ranges from 2.0 to 3.5%, and a linear range of 50 to 150%. This method significantly improves the quality control and release inspection efficiency of PTH1–34 and may be further developed and validated as an alternative to the existing United States Pharmacopeia and European Pharmacopoeia inclusion methods. This method also provides a platform for the high-throughput screening of PTH1–34 analogs.

Abstract Necroptosis, a caspase-independent regulated cell death, is primarily mediated by the serine/threonine kinases RIPK1 and RIPK3, and the mixed lineage kinase domain-like protein (MLKL). Targeting necroptosis is a validated therapeutic strategy for various diseases. We screened compound 1, a novel benzimidazole-based necroptosis inhibitor, from our in-house compound library. We assessed its inhibitory roles and mechanisms in blocking HT-29 cell necroptosis. HT-29 cells were treated with pan caspase inhibitor Z-VAD-FMK + Smac mimetic (TSZ), or Z-VAD-FMK + cycloheximide (TCZ), then with tumor necrosis factor α (TNFα) to induce necroptosis in vitro. Prior to stimulation, cells were exposed to compound 1. GSK'843 served as a control drug. HT-29 cells were treated with TNFα + Smac mimetic (TS) or TNFα + cycloheximide (TC) to induce apoptosis in vitro. Cell viability, cell death, and necroptotic cells were evaluated by luminescence-based CellTiter-Lumi assay or flow cytometry. Western blots, immunoprecipitation, and KINOMEscan technology were used to assess RIPK1, RIPK3, and MLKL's involvement in compound 1's mechanisms. Compound 1's roles in mouse TNFα induced systemic inflammatory response syndrome (SIRS) in mice were also investigated by assessing body temperature, mouse survival rate, and interleukin (IL)-β and IL-6 levels in respective tissues. We found that necroptosis triggered by TSZ or TCZ was effectively mitigated by compound 1, showing a dose-responsive inhibition, and it could protect mice from TNF-induced SIRS. The mechanism study showed that compound 1 could interact with RIPK1, inhibiting RIPK1 phosphorylation activation to block necrosome formation in necroptotic cells. In summary, compound 1 is a promising lead compound for developing treatments targeting diseases associated with necroptosis.

The mitochondrial pyruvate carrier (MPC) exists in the mitochondria inner membrane which transports pyruvate to the mitochondrial matrix. Evidence shows that MPC is the breakthrough point to study the regulation of basic energy metabolism, the dysfunction of which may lead to metabolic disturbance. Due to its important metabolic function, MPC has been considered a potential therapeutic target for diabetes, alopecia, cancers, neurodegenerative diseases, and liver metabolic diseases. However, MPC' protein crystal structure is still not clear as the proteins involved were only identified 10 years ago, making it difficult to carry out rational drug design based on receptor structure. In this review, we summarize the latest applications of MPC in different diseases and discuss the recent advances in pharmacochemical strategies of small-molecule inhibitors of MPC, hoping to promote the development of specific MPC inhibitors.

Abstract The gene delivery systems (GDS) for lung cancer (LC) has made significant progress over the past 12 years, yet, there is a great challenge in its clinical application due to low delivery efficiency. This study aims to explore research fields related to gene therapy for LC and predict future directions from a bibliometric perspective. The Web of Science Core Collection collects articles and reviews on GDS for LC published from 2010 to 2022. Comprehensive bibliometric and visual analyses were performed using CiteSpace, VOSviewer, R-Bibliometrix, and Microsoft Excel. The analysis showed that the number of publications on GDS for LC has been increasing over the past 12 years, highlighting the growing interest and research efforts in this area. A rigorous examination of keywords and research hotspots revealed that the themes such as “complex,” “transfection,” “RNA interference,” “extracellular vesicle,” “co-deliver,” “resistance,” etc. dominate the field of GDS for LC. These findings indicated that the research in GDS for LC is evolving, with a noticeable shift toward addressing challenges related to delivery efficiency, transfection methods, and overcoming resistance mechanisms in gene therapy. The comprehensive study provides an overview of the literature on GDS for LC and identifies areas that require further exploration and development. By highlighting emerging research hotspots, our bibliometric analysis offers valuable insights to scholars and researchers, aiding in the identification of gaps, and guiding future efforts toward the development of GDS with more efficiency for LC therapy.

Abstract Chushi Weiling Decoction (CWD) is a classic prescription in traditional Chinese medicine used to treat dampness-heat skin diseases. However, the material composition of CWD and its therapeutic mechanism remained largely unknown. This study aimed to investigate the pharmacological material basis of CWD and their potential therapeutic effects using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS), gas chromatography-mass spectrometry (GC-MS), and network pharmacology. In this work, UPLC-Q-TOF-MS and GC-MS technologies were used to identify the main components of CWD. The UPLC-Q-TOF MS analysis was performed on a Thermo-Accucore aQ C18 (100 mm × 2.1 mm, 2.6 μm; ThermoFisher, United States) with a mobile phase consisting of acetonitrile–0.1% formic acid aqueous solution in MSE mode. The GC-MS analysis was performed on an HP-5MS UI (0.25 mm × 30 m × 0.25 μm; Agilent, United States) of headspace injection. Treatment mechanisms of eczema and herpes zoster were explored using network pharmacology methods and enrichment analysis. Our data showed that there were 194 compounds identified using UPLC-Q-TOF-MS and 92 compounds identified using GC-MS. The mass spectrometric fragmentation rules of terpenoids, flavonoids, phenylpropanoids, phenolic acid esters, and alkaloids in CWD were summarized. Network pharmacology provided targets and pathways, and molecular docking indicated that alisol J 23-acetate, kaempferol, anomalin, and cinnamaldehyde tend to combine with target proteins in a good case at a low level of binding energy. Given the above, this study provides a reference for the material basis of CWD, and suggests that CWD may play a therapeutic role in eczema and herpes zoster by (1) anti-inflammatory, antiviral, mediating immune response; and (2) regulating steroid metabolism.

Abstract Trichodestruxins A–D are cyclic peptides isolated from the plant endophyte fungus Trichoderma harzianum with inhibitory activities against the proliferation of tumor cells. This study aimed to modify the structure of trichodestruxin D (TD-(R)) to improve its antitumor activity and analyze the structure–activity relationship (SAR) to provide references for lead optimization. In this study, seven TD-(R) derivatives (TD-(S), TD-1, 2, 3, 4, 5, 6) were designed by different strategies, namely amino acid mutation, configuration switching, replacement of ester with amide, and N-methylation/demethylation. Those derivatives were prepared by a solid-phase peptide synthesis strategy, and structurally characterized by high-resolution mass spectra. The inhibitory activities of the peptides against the lung carcinoma A549 cells were assessed by determining cellular proliferation and migration using CCK-8 and a 24-well migration plate. Our data confirmed the inhibitory effect of those derivatives on A549 cell proliferation, among which TD-(S), TD-1, and TD-2 displayed higher inhibitory activity compared with the control (DMSO) group, but their inhibitory activity was slightly decreased than that of TD-(R). The inhibitory activity of TD-3, TD-4, and TD-6 on A549 cell migration was much better than that of TD-(R). SAR studies demonstrated a pivotal role in the configuration of the residue of 2-hydroxy-4-methyl-pentenoic acid and some residues in the structure of TD-(R). In conclusion, TD-3, TD-4, and TD-6 may be potential agents for the treatment of cancer migration, and our modification methods will provide a reference for the development of anticancer drugs in the future.

Pegasus laternarius Cuvier (Hai-E Yu) is a marine traditional Chinese medicine that has been used to treat cancers and reduce inflammation. Previous chemical investigations have only revealed the occurrence of high levels of protein, fatty acids, and a large number of steroids, thus more active compounds in P. laternarius still need to be further discovered. The present study aims to search for new bioactive constituents of P. laternarius with cytotoxic effects and nitric oxide (NO) inhibitory activities. In this work, 16 pure compounds from the ethyl acetate fraction of Pegasus laternarius Cuvier were successively obtained by various chromatographic techniques, and the structure of the isolates was elucidated by spectroscopic analyses. The isolated and identified compounds included one 2H-1,2,3-triazole-4-carboxylate derivative (1), two oxadiazines (2, 3), two amino acids (4, 5), three nucleosides (6–8), three steroids (9–11), and five others (12–16). All the obtained compounds were evaluated for their antitumor activity on A549 and HCT-116 cell lines along with their inhibitory effects on lipopolysaccharide-induced NO production in RAW264.7 cells. The triazole compound 1 was found to exhibit moderate cytotoxicity against two human cell lines (A549 and HCT-116) with IC50 values of 44.5 and 32.9 μmol/L, respectively. The steroid compound 10 inhibited NO production with IC50 values lower than 50 μmol/L. Consequently, this study provides insight into the cytotoxic and NO inhibitory activities of the marine traditional Chinese medicines in Hai-E-Yu.

Calcitriol (1α,25-dihydroxyvitamin D3, 1), a classical vitamin D drug, is indicated primarily in the treatment of patients with postmenopausal osteoporosis and renal osteodystrophy. In this study, a practical synthesis of calcitriol (1), from readily available commercial vitamin D2 (5) via hub intermediate 18, has been accomplished in 9% overall yield. This semi-synthetic process embedded four prominent elements of vitamin D chemistry: (1) cheletropic sulfur dioxide (SO2) adduction for the isomerization of the characteristic triene from (5Z,7E) to (5E,7E), or for the protection of the triene for selective ozonolysis of the side chain, and cheletropic extrusion of SO2 from the adduct in ethanolic sodium bicarbonate to retrieve the triene; (2) direct, regio- and stereoselective 1α-hydroxylation of 3β-TBS-protected (5E)-calciferol intermediate 19 using selenium dioxide in the presence of N-methylmorpholine N-oxide as a re-oxidant in a hot mixture of methylene chloride and methanol; (3) nickel(0)-mediated conjugate addition of the 22-iodide 23 to electron-deficient ethyl acrylate followed by Grignard reaction with methylmagnesium bromide to construct the calcitriol side chain; and (4) triplet-sensitized photoisomerization of 26 to access the bioactive (5Z,7E)-triene in calcitriol (1). The high-performance liquid chromatography purities of batches of the synthesized calcitriol (1) were consistently more than 99.9%, with related substances listed in the USP 2023 and EP 11.0 well controlled. This robust process proved amenable to pilot scale-up and industrial production. 26,27-Hexadeutero calcitriol (4), a deuterium-labeled calcitriol derivative, is useful as the internal standard in the bioanalysis for the quantification of calcitriol in serum. 4 was efficiently synthesized in an integrated manner from hub intermediate 18 in 48% yield.

Abstract Microfluidic technology facilitates precise control over fluid mixing and interactions between the components, including self-assembly and precipitation. It offers new options for accurately manufacturing particles and holds significant potential in advancing micro/nanoparticle drug delivery systems (DDSs). Various microchannel/microfluidic chips have been explored to construct micro/nanoparticle DDSs. The precise manipulation of particle size, morphology, structure, stiffness, surface characteristics, and elasticity through microfluidic technology relies on specific microchannel geometrical designs and the application of exogenous energy, adhering to the principles of fluid motion. Consequently, this enables reproducible control over critical quality attributes (CQAs), such as particle size and distribution, encapsulation efficiency, drug loading, in vitro and in vivo drug delivery profiles, Zeta potential, and targeting capabilities, for micro/nanoparticle DDSs. In this review, we categorize microfluidic techniques and explore recent research developments in novel microchannel structures spanning the past 5 years (2018–2023) and their applications in micro/nanoparticle DDSs. Additionally, we elucidate the latest manipulation strategies of microfluidic techniques that impact foundational structures related to the CQAs of micro/nanoparticle DDSs. Furthermore, we offer insights into the industrial applications and challenges microfluidic techniques face in the context of novel micro/nanoparticle DDSs.